Reported Saturday, Bicara Therapeutics Reports 57% Confirmed Overall Response Rate With 750mg Ficerafusp Alfa Weekly Plus Pembrolizumab, Supporting Pivotal Interim Analysis
Benzinga Newsdesk 11 months ago
News
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study interim
- Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study interim analysis
- Totality of data demonstrates that greater TGF-β inhibition, observed at 1500mg of ficerafusp alfa, drives deeper tumor responses that translate to more durable outcomes for patients
- Pivotal FORTIFI-HN01 optimal dose declaration expected in first quarter 2026